-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Esophageal cancer is a type of cancer that is difficult to treat and begins in the inner layer of the esophageal (mucous membrane) and grows outwards.
main types of esophageal cancer are squamous cell carcinoma and adenocarcinoma.
esophageal cancer is the seventh most common cancer and sixth leading cause of death in the world.
estimates that there will be more than 572,000 new cases of esophageal cancer diagnosed globally in 2018, with nearly 509,000 deaths from the disease.
, it is the fourth leading cause of cancer death in China, after lung, stomach and liver cancers.
high incidence of esophageal cancer in China may be related to China's "hot eating" diet.
this sBLA is based on the positive results of key Phase 3 clinical trial KEYNOTE-590.
In this trial, Keytruda's combination therapy with chemotherapy significantly improved the patient's total and non-progressed survival compared to chemotherapy, regardless of whether the patient's tumor expressed PD-L1 and the tumor histological characteristics.
interim analysis presented at this year's ESMO Conference showed that Keytruda combined therapy reduced the risk of death by 27% compared to chemotherapy at a medium follow-up time of 10.8 months (HR=0.73,95% CI, 0.62-0.86, p-lt;0.0001).
total survival (OS) in patients reached 12.4 months, and in the chemotherapy group it was 9.8 months.
Keytruda combination therapy in KETNOTE-590 clinical trial lifetime data (Photo: Mercadon.com) It is worth noting that in the Asian patient sub-group, this combination therapy showed better outcomes than the entire patient population, reducing the risk of death by 36% (HR=0.64) and the risk of disease progression or death by 41% (HR=0.59).
: .1) FDA Grants Grants Review to Merck's Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Plus Filmy as First-Treatment Line for Locally Advanced Unresectable or Metastatic Esophageal and Gastroesophal Junction. Retrieved December 17, 2020, from。
